TOP HEADLINES

Featured Story

  • Sequenom scores a blow against Illumina in prenatal Dx patent fight

    Sequenom scored against Illumina's Verinata Health in a ruling at the U.S. Patent and Trademark Office involving noninvasive prenatal genetic diagnostic tech. Wasting no time, executives plan to use that decision as a weapon in an ongoing legal battle between the two California companies.

Eventus attracts $2.72M for breast cancer Dx testing and commercial expansion

Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests.

An acquisition helps carry ERBA Diagnostics to a (small) 2013 profit

ERBA Diagnostics has something to crow about for 2013. Year-over-year, the Florida in vitro diagnostics outfit swung from a net loss to a small profit, aided, in part, by a surge in new revenue stemming from a 2012 acquisition. The company said it is eyeing more M&A deals in 2014.

Qiagen licenses biomarker for rare blood disorders with a molecular Dx in mind

Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.

UCLA, working with a Chinese partner, will build a high-tech Dx lab in Shanghai

The University of California and a Chinese company will launch a high-end medical lab in Shanghai expected to handle molecular diagnostics and other tests for Chinese patients. They're billing the initiative as the first of its kind between a Chinese company and a U.S. academic medical center.

Philips touts encouraging results from an early test of its hand-held cardiac blood Dx

Philips Healthcare is touting some positive early results from a field study of its new hand-held blood test to spot patients at high risk for heart attacks or other "acute cardiac events."

MORE NEWS

From Our Sister Sites

FierceBiotechIT

Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.

FierceBiotechIT

Europe is embarking on the second, decadelong part of its public-private partnership to improve drug development, with Parliament agreeing this week to contribute to the €3 billion ($4.1 billion) program. And the "yes" vote will mean more cash for IT.